What is the clinical benefit of extended adjuvant treatment?

Extended adjuvant treatment (EAT) is a post-surgery therapy used to help manage the risk of cancer recurrence. It involves extending an existing course of treatments beyond their typical durations. For example, if a patient was given breast cancer treatments for three months following surgery, EAT would recommend that the patient continue with either chemotherapy or endocrine therapy for up to five years in order to significantly reduce their risk of early relapse and improve long-term survival outcomes.

In clinical studies, EAT has been shown to offer significant benefits when compared with shorter courses of treatment; one study found that postmenopausal women using exemestane after 5 years had 27% lower risks of breast cancer recurrence than those who took it for only 3 years, regardless of whether they were hormone receptor positive or negative. Furthermore, continual use without interruption may be particularly beneficial as it helps ensure consistent levels and duration of drug exposure throughout the extended period.

Overall, there is increasing evidence that extended adjuvant therapy can significantly contribute towards improved prognosis in many types of cancers - potentially providing additional protection against early relapse while also improving overall survival rates.